Although TAZ and YAP have been shown to be activated oncoproteins in a number of carcinomas [33, 34] and sarcomas [35], genetic alterations are rare with the exception of the WWTR1-CAMTA1 [36–38] and YAP1-TFE3 gene fusions in epithelioid hemangioendothelioma (EHE) [39]. This evidence concerns the gene TFE3 and epithelioid hemangioendothelioma.